Assays Used for Discovering Small Molecule Inhibitors of YAP Activity in Cancers

Subhajit Maity1, Artem Gridnev1, Jyoti R Misra1

  • 1Department of Biological Sciences, University of Texas at Dallas, Richardson, TX 75080, USA.

Cancers
|February 25, 2022
PubMed

Insights

Dysregulated YAP/TAZ proteins drive cancer growth, metastasis, and resistance. This study reviews assays for discovering small molecule inhibitors targeting YAP-transcriptional activity for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) are key Hippo signaling pathway effectors.
  • YAP/TAZ are frequently overexpressed and hyperactivated in human cancers, promoting tumor growth and survival.
  • These coactivators are crucial for cancer stem cell properties, metastasis, and chemotherapy resistance.

Purpose of the Study:

  • To review and discuss assays for high-throughput screening (HTS) of small molecule libraries.
  • To identify potent inhibitors of YAP/TAZ-transcriptional activity.
  • To evaluate the advantages and limitations of various screening assays for YAP/TAZ inhibition.

Main Methods:

  • High-throughput screening (HTS) assays for YAP/TAZ-transcriptional activity.
  • Small molecule library screening for hit identification.
  • Hit validation assays for inhibitor potency and specificity.

Main Results:

  • YAP/TAZ nuclear localization and association with TEAD transcription factors drive oncogenic gene expression.
  • YAP/TAZ promote cancer cell proliferation, inhibit apoptosis, and contribute to tumor metastasis.
  • YAP/TAZ influence tumor immunity via PD-L1 expression and impact chemotherapy resistance.

Conclusions:

  • YAP/TAZ are critical targets for novel cancer therapeutics.
  • Effective assays are essential for discovering potent YAP/TAZ inhibitors.
  • Targeting YAP/TAZ transcriptional activity holds promise for comprehensive cancer treatment strategies.